Review
Open access
Sep 2026
Mechanisms and Clinical Breakthroughs of Bispecific Antibody–Drug Conjugates (BsADCs)- Dual‑Targeting Strategies Exemplified by EGFR/HER3
BsADCs represent a new promising strategy to address tumor heterogeneity, antigen escape, and bypass signaling as well as improve targeted payload delivery and can serve as a theoretical background for designing and testing BsADCs.
Bo-Wen Cui
· Theoretical and Natural Scie... · 0 citations